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Rheumatoid arthritis (RA) is considered to be, in many respects, an archetypal
autoimmune disease that causes activation of pro-inflammatory pathways resulting in joint
and systemic inflammation. RA remains a major clinical problem with the development
of several new therapies targeted at cytokine inhibition in recent years. In RA, biologic
therapies targeted at inhibition of tumor necrosis factor alpha (TNFα) have been shown
to reduce joint inflammation, limit erosive change, reduce disability and improve quality
of life. The cytokine TNFα has a central role in systemic RA inflammation and has also
been shown to have pro-inflammatory effects in the brain. Emerging data suggests there
is an important bidirectional communication between the brain and immune system in
inflammatory conditions like RA. Recent work has shown how TNF inhibitor therapy in
people with RA is protective for Alzheimer’s disease. Functional MRI studies to measure
brain activation in people with RA to stimulus by finger joint compression, have also shown
that those who responded to TNF inhibition showed a significantly greater activation
volume in thalamic, limbic, and associative areas of the brain than non-responders.
Infections are the main risk of therapies with biologic drugs and infections have been
shown to be related to disease flares in RA. Recent basic science data has also emerged
suggesting that bacterial components including lipopolysaccharide induce pain by directly
activating sensory neurons that modulate inflammation, a previously unsuspected role
for the nervous system in host-pathogen interactions. In this review, we discuss the
current evidence for neuro-inflammation as an important factor that impacts on disease
persistence and pain in RA.
Keywords: neuroinflammation, rheumatoid arthritis, tumor necrosis factor alpha, neuroimaging, infection,
lipopolysaccharide
INTRODUCTION
Rheumatic diseases include some of the most common chronic
disorders worldwide. Of these, rheumatoid arthritis (RA) is
considered to be, in many respects, an archetypal autoimmune
disease (Feldmann andMaini, 2010). RA causes activation of pro-
inflammatory pathways resulting in joint and systemic inflamma-
tion and remains a major clinical problem (McInnes and Schett,
2011). Treatments with immune-modulatory drugs, including
biologic therapies, have revolutionized its management. New
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Oxygenase; CS, Corticosteroids; CSSERP, Chemo-Somatosensory Event-Related
Potentials; DAMPs, damage associated molecular patterns; DMARD, Disease-
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Tensor Imaging; ESR, Erythrocyte Sedimentation Rate; fMRI, Functional Magnetic
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therapies target relevant cytokines such as tumor necrosis fac-
tor alpha (TNFα) and immune cells such as B cells. In RA,
biologics have been shown to reduce joint inflammation, limit
erosive change, reduce disability and improve quality of life
(Scott et al., 2010). Biologics are mainly co-administered with
disease-modifying drugs such as methotrexate when the latter
are found to achieve insufficient disease control on their own
(Firestein, 2003). Recent work using functional neuroimaging
has suggested that TNF inhibitors may also reduce central ner-
vous system activity related to inflammation-induced pain in
people with RA using brain neuroimaging (Rech et al., 2013).
Classically, the term “neuro-inflammation” has implicated the
activation of microglia and astroglia which in turn activate
the expression of pro-inflammatory cytokines and chemokines
in a variety of conditions including Alzheimer’s disease (AD)
(O’Callaghan et al., 2008). However, the trigger(s) for activa-
tion of a potential neuro-inflammatory process and furthermore
its measurement in clinical disease is not always straightfor-
ward to decipher. Several groups have utilized animal mod-
els to discover that although certain features of inflammation
are typical for the pro-inflammatory response systemically e.g.,
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interleukin-6 (IL-6), interferon-β (IFNβ), these are not observed
in the brain, but activation of TNFα does appear to main-
tain pro-inflammatory activity in the brain as it does system-
ically (Skelly et al., 2013; Thomson et al., 2014). Some of
the basic science observations can be extended to RA, where
Chou et al. (2010) observed that people with RA receiving
TNF inhibitor treatment (infliximab, etanercept, adalimumab)
showed a reduction in the risk of developing AD compared
to controls (Chou et al., 2010). The risk of AD was not
affected by exposure to other Disease-Modifying Anti-Rheumatic
Drugs (DMARDs) used in RA. Recent work by Detrait et al.
(2014) has also shown that peripheral administration of TNF
inhibitors in mice counteracts the amyloid-induced increase of
hippocampal TNFα levels and memory deficits in mice. In this
review, we explore the theme of neuro-inflammation in RA.
Although as yet, the cause-and-effect relationship between infec-
tion, autoimmunity, neural correlates and RA disease activity are
not understood mechanistically, we review the current status of
the field.
CURRENT CONCEPTS IN THE PATHOGENESIS OF
RHEUMATOID ARTHRITIS
RA is an immune-mediated pro-inflammatory disease, often
resulting in chronic disability, early mortality, systemic compli-
cations and high socioeconomic burden on society as a whole
(McInnes and Schett, 2011). There has been a vast improve-
ment in our understanding of this condition over the last few
decades, resulting in improved treatments which are now initi-
ated early in order to maximize and maintain disease remission
(van Vollenhoven, 2010).
Risks for developing RA involve a complex interplay between
genotype, environment and lifestyle factors such as smoking
(Mahdi et al., 2009). Twin studies have shown a concordance
rate of 15–30% among monozygotic twins and 5% among dizy-
gotic twins (MacGregor et al., 2000). Genome-wide associa-
tion analyses have uncovered immune regulatory factors that
may underlie the disease; including PTPN22 among the Single
Nucleotide Polymorphisms (SNPs) identified (Wellcome Trust
Case Control Consortium, 2007). An association with HLA-
DRB1 has been established for RA patients who are positive
for rheumatoid factor or anti-citrullinated peptide antibodies
(ACPA) (Gregersen et al., 1987). In keeping with the role of
HLA-DRB1 in antigen presentation, a number of studies over the
last 2 decades have shown that auto-reactive immune responses
are mediated by T-cell repertoire selection, antigen presenta-
tion or changes in peptide affinity (Panayi, 2006). The shared
epitope (SE), carried by the vast majority of RA patients, is
a 5-aa sequence motif in the third allelic hypervariable region
of the HLA-DRβ chain. Proposed explanations for the link
between RA and the SE include molecular mimicry of the SE
by microbial proteins, increased T cell senescence induced by
SE-containing HLA molecules and a potential pro-inflammatory
signaling function that is unrelated to the role of the SE in anti-
gen recognition (Weyand and Goronzy, 1990; De Almeida et al.,
2010).
Gene-environment interactions are also important in RA
development. Smoking and other environmental risks to the lung
such as silica exposure, increase the risk of RA in people with
susceptibility HLA-DR4 alleles (Symmons et al., 1997; Klareskog
et al., 2008). Smoking and HLA-DRB1 alleles synergistically
increase one’s risk of developing the anti-citrullinated protein
antibodies (ACPA) that are present in the majority of patients
with RA (Klareskog et al., 2008). It has therefore been proposed
that environmental stress in the lung or other mucosal surfaces
may promote post-translational modifications through activa-
tion of peptidyl arginine deiminase, type IV (PADIV), resulting
in citrullination of mucosal proteins. Loss of tolerance to the
neoepitopes generated by citrullination can be detected clini-
cally in people with RA by the ACPA response (Vincent et al.,
1999).
It has long been recognized that infectious agents such as
cytomegalovirus, E. coli, Epstein Barr virus, parvovirus, and pro-
teus species may play a role in RA. Recently, the oral pathogen
Porphyromonas gingivalis has been implicated in the pathogene-
sis of RA (Mikuls et al., 2014). Products of infectious agents e.g.,
heat shock proteins and enzymes responsible for citrullination
have been shown in several models to induce immune reactivity.
For example, several citrullinated self-proteins can be identi-
fied in ACPA assays, including alpha enolase, keratin, fibrinogen,
fibronectin, collagen, and vimentin (van der Woude et al., 2010).
Although unifying mechanisms for the link between infection
and RA autoimmunity are not entirely established, the theory of
molecular mimicry has been proposed (van Heemst et al., 2014).
The formation of immune complexes during infection may trig-
ger the induction of rheumatoid factor, which is a high affinity
autoantibody against the Fc portion of immunoglobulin, often
used in the diagnosis of RA (De Rycke et al., 2004). A link has been
described between RA and periodontal disease: Porphyromonas
gingivalis produces PAD1V which can promote citrullination of
mammalian proteins (Wegner et al., 2010). Recently, the gastroin-
testinal microbiome has also been implicated in the development
of autoimmunity (Scher et al., 2012).
Emerging data suggests there is an important impact of bidi-
rectional communication between the brain and immune system
that has a significant impact on RA symptoms. The onset of
RA is associated with adverse life events and infectious trig-
gers, where links between the hypothalamic-pituitary-adrenal
axis and autoimmunity have been shown (Sokka et al., 2009;
Capellino et al., 2010). The impact of external factors such as
infections and their impact on disease activity in RA including
joint pain/swelling will be discussed further in the following sec-
tions. One feature of established RA includes the presence of
rheumatoid factor, which is an IgM complex of antibodies to
IgG found circulating in RA (Mellor, 1959). Cerebrospinal fluid
rheumatoid factor has been demonstrated in case reports of cen-
tral nervous system manifestations of RA. (Markenson et al.,
1979; Inan et al., 2011) Recent studies suggest that circulating
immune complexes can elicit a neuro-inflammatory response
in the brain. Teeling et al. (2012) showed that in the pres-
ence of antigen, antibodies can lead to local immune complex-
mediated inflammatory reaction in the brain parenchyma and
directly induce local tissue damage through the recruitment and
activation of microglia through Fcγ receptors (Teeling et al.,
2012).
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THE ROLE OF CYCLO-OXYGENASE AND PROSTANOIDS IN
NEURO-INFLAMMATION
Several of the brain effects induced by cytokines such as TNFα
are thought to be mediated by regulating the expression of
cyclo-oxygenase (COX) enzymes (mainly COX-2) and genera-
tion of prostanoids. Under usual physiological conditions, these
inflammatory mediators are absent in the brain or found in
low levels. After brain injury or insult, there can be induction
of pro-inflammatory mediators in astrocytes, microglia, neu-
rons and endothelial cells which results in the development of
neuro-inflammatory conditions. Recently, the COX-2 inhibitor
celecoxib has been shown to reduce functional connectivity mea-
sured by functional MRI in an animal model of osteoarthritis
(Upadhyay et al., 2013). In their study, Upadhyay et al. (2013)
showed a reduction in blood oxygenation in recognized brain
pain centers including the thalamus, hippocampus, periaqueduc-
tal graymatter and nucleus accumbens in arthritic rodents treated
with celecoxib. Human studies in patients with chronic knee
osteoarthritis have also shown that COX inhibitors e.g., valde-
coxib, reduce spontaneous brain pain activation signals measured
by functional brain MRI (Parks et al., 2011).
One of the earliest studies in human subjects by Ho et al.
(2001) demonstrated that neuronal COX-2 expression was
increased in post-mortem samples of people with Alzheimer’s
disease and correlated with clinical progression of dementia
(Ho et al., 2001). In Alzheimer’s disease, the classical neuro-
pathological changes include deposition of neurofibrillary tangles
and β amyloid (Aβ). Alzheimer’s dementia is typified by activa-
tion of microglia and astrocytes in response to Aβ deposition,
leading to a release of a variety of factors including the cytokines
TNFα and IL-1β, free radicals such as nitric oxide, superoxide and
cyclo-oxygenase pathway derived prostanoids (Combs et al., 2001;
Hull et al., 2006;Medeiros et al., 2007). Evidence for the activation
of the COX pathway has come from neuro-inflammatory diseases
that include Alzheimer’s disease, Parkinson’s disease and multiple
sclerosis. For example, in a mouse model of Parkinson’s disease,
Hunter et al. (2007) showed that celecoxib, a COX-2 inhibitor,
inhibited neuronal effects in rats injected with LPS. They found
that a number of effects were reduced in rats treated with cele-
coxib, including inflammation and nigral dopaminergic neuronal
loss. It is therefore possible that non-steroidal anti-inflammatory
drugs (NSAIDs) such as celecoxib could have an inhibitory effect
on neuro-inflammation and could have an impact on delaying
neurodegenerative effects.
CAN INFECTION INFLUENCE RHEUMATOID ARTHRITIS
PAIN?
The central nervous system is involved in immune regulation and
homeostasis, with neuro-immunological interactions regulating
disease development in animal models of arthritis (Chiu et al.,
2013). Peripheral inflammation triggered by synovial inflamma-
tion in RA stimulates the increased release of cytokines (Taylor,
2014). Cytokine inhibitors administered to patients with a high
disease load have also been shown to suppress RA arthritic disease
activity (Feldmann and Maini, 2010). More recently, microar-
ray analysis of brain extracts from mice injected peripherally
with the gram-negative bacterial stimulus of lipopolysaccharide
(LPS) has indicated an increase in cytokine expression (Thomson
et al., 2014). The cytokine up regulation observed was found to
be elicited by a Toll-Like Receptor (TLR)-mediated interferon
response in mice injected peripherally with LPS (Thomson et al.,
2014).
Data has emerged from animal models to suggest that micro-
bial components including LPS can activate sensory neurons
directly (Chiu et al., 2013). In their elegant studies, Chiu et al.
(2013) applied heat-killed S. aureus to dorsal root ganglia (DRG)
sensory neurons and demonstrated an induction of calcium flux
and induced action potential firing. S. aureus was found to
directly activate nociceptors in the Nav1.8-lineage (Chiu et al.,
2013). Other experiments showed that neuronal responses by
the Nav 1.8 nociceptor could be activated through heat-killed
streptococcus, Listeria monocytogenes, Mycoplasma fermentans,
Helicobacter pylori, Pseudomonas aeruginosa, and Escherichia coli.
Variations in the pattern of nociceptor responsiveness between
bacteria could indicate that strain-specific ligands act through
different mechanisms.
THE IMPORTANCE OF TNF AS A PRO-INFLAMMATORY
CYTOKINE IN RHEUMATOID ARTHRITIS
Biologic therapies have been used to treat severe RA since 1997
and have beenmanufactured to target specific elements of inflam-
mation pathways. They include anakinra, an IL-1 antagonist;
abatacept, which down-regulates T cell activation; rituximab, a
chimeric anti-CD20 antibody which reduces B cell activation and
infliximab, adalimumab and etanercept which inhibit TNF activ-
ity (Malaviya and Ostor, 2012). The European League Against
Rheumatism (EULAR) and American College of Rheumatology
(ACR) provide guidance on suitable indications for commenc-
ing biologic therapy for RA recommending treatment for disease
which is active despite optimization of conventional DMARDs or
for patients with high disease activity and risk factors for poor
outcome (ACPA and rheumatoid factor positivity and erosive
disease on radiography) (Smolen et al., 2014).
As mentioned above, TNFα is a key cytokine in the patho-
genesis of synovial inflammation in RA, however, it has also
been shown to play a vital role in fighting infections in animal
models (Parks et al., 2011). TNFα is a type II transmembrane pro-
tein, cleaved by TNF-α converting enzyme (TACE) to a soluble
form. It acts as a ligand for two receptors, TNFR1 and TNFR2,
to enable transduction of anti-apoptotic, pro-inflammatory sig-
nals. TNFα-mediated functions include phagosome maturation,
autophagy inhibition and apoptosis following activation of cas-
pase 8 by TNFR1 (Harris and Keane, 2010). By inhibiting these
actions, anti-TNF therapy causes suppression of the immune
system (Tracey et al., 2008) and improves outcomes for sup-
pressing inflammation and function clinically. However, TNF
inhibitor therapy has also been shown to induce neurological
events (Kaltsonoudis et al., 2014).
TYPES OF INFECTIONS
The risk of developing infections is heightened in RA. In the
following sections we describe the more common infections
observed in people with RA. Since TNF inhibitor therapy can
increase the incidence of infections in RA, it is possible that
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increased infections observed in RA during TNF inhibitor ther-
apy could be a cause of RA flares, which in turn could have an
impact on RA disease activity.
BACTERIAL INFECTIONS
Bacterial infections contribute to three quarters of infections
in patients taking corticosteroids (CS), DMARDs or biological
agents for RA and spondyloarthritis with respiratory tract infec-
tions being the most common (Germano et al., 2014). A recent
systematic review of over 23,000 patients using anti-TNF therapy
in the treatment of RA, juvenile idiopathic arthritis, ankylos-
ing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease,
has further characterized infections associated with biologics.
It showed that infections leading to a cessation in treatment
included pneumonia (6.6%), bacterial arthritis (2.8%), gastro-
intestinal abscess (2.1%), and cellulitis (1.1%). In this study
the highest rates of serious infection events were seen in RA
and, within this subset of patients, cellulitis and pneumonia
were the most common types of infection (Burmester et al.,
2013).
MYCOBACTERIAL INFECTIONS
TNFα is a key mediator in the host immune defense against
mycobacterium tubercule bacillus (TB) infections leading to acti-
vation of macrophages, cell recruitment, granuloma formation
and maintenance (Bean et al., 1999). In murine models, the neu-
tralization of TNFα increases susceptibility to primary TB and
injection of soluble TNFα receptors can cause activation of TB
in infected mice (Senaldi et al., 1996). TNF inhibitor therapy may
also result in active tuberculosis in humans carrying a latent infec-
tion (Keane et al., 2001). A 3 year study by Tubach (Tubach et al.,
2009) found 69 cases of tuberculosis (40 in RA) in patients treated
with anti-TNFα. Tuberculosis has been found to occur more fre-
quently in patients taking anti-TNFα therapy than in the general
population with a standardized incidence rate varying between
12 and 35 (Ramiro et al., 2014). There is data to suggest that the
risk of tuberculosis is not constant for all anti-TNFαmedications,
with soluble TNFα receptors resulting in a lower risk of infection
than monoclonal antibodies (Tubach et al., 2009).
VIRAL AND OPPORTUNISTIC INFECTIONS
Some studies separate opportunistic infections from a broader
definition of infections, serious infections, or serious infec-
tion events. In a study of 23, 458 patients on anti-TNFα
therapy 20 patients (14 patients with RA) developed oppor-
tunistic infections (excluding TB or oral candidiasis) including
oesophageal candidiasis, aspergillosis, candida sepsis, coccid-
iomycosis, cytomegalovirus, herpes zoster, and nocardiasis
(Burmester et al., 2013).
Analysis of a French registry for opportunistic infections in
patients taking biologic therapy for any condition found that 43
patients had opportunistic infections; 29 on infliximab, 10 on
adalimumab and 4 on etanercept (Salmon-Ceron et al., 2011).
Twenty-six of these were experienced by patients with RA and,
of the total 43, 10 patients required intensive care and four died.
When interpreting these findings it should be noted that patient
information included in registry data is unlikely to be subject to
the close scrutiny and follow-up afforded as those from clinical
trials. Thus, systematic reviews of randomized controlled trials
and open-label trials may provide more robust data.
The risk of herpes zoster infection is higher in those with
autoimmune conditions than in the general population (Wolfe
et al., 2006) and rates of the disease are significantly increased
for those receiving anti-TNF therapy (andmonoclonal antibodies
in particular), with an increased rate with greater age and higher
disease activity at baseline (Strangfeld et al., 2009). However, a
more recent systematic review including three studies investigat-
ing skin infections in patients taking biologic therapies calculated
an adjusted hazard ratio range of 1.0–1.7 for herpes zoster infec-
tion, reflecting no significant risk of the infection when taking
biological DMARDs (Ramiro et al., 2014).
RISK OF INFECTION
Randomized controlled trials are mixed in their demonstration
of an association between biologic therapy and infectious adverse
events (Lipsky et al., 2000; Keystone et al., 2004; Wallis et al.,
2004). It has been demonstrated that of the patients with RA
who acquire serious infections whilst taking biologics, 32% per-
manently discontinue therapy (Burmester et al., 2013) leading to
significant compromise in therapeutic options for the treatment
of the patient’s arthritis.
The higher rate of infectious events may result from an
increased risk of infection inherent to RA (Doran et al., 2002a)
(though this appears to have reduced over the last 50 years (Ni
Mhuircheartaigh et al., 2013), which is thought to be secondary to
immune disturbance associated with disease pathogenesis and the
use of immune-modulators to control the condition (Doran et al.,
2002a,b). An inherent risk of infectionmakes establishing a causal
link between biologic DMARDs and infections more difficult. For
this reason systematic reviews and meta-analyses of clinical trials
and registry data are useful tools to investigate the rare adverse
events, by pooling data for large cohorts of patients.
Recent work has suggested that the blood brain barrier (BBB)
may be compromised in RA with macrophages being recruited
from the systemic circulation via intercellular adhesion molecule
(ICAM) expression on the endothelium (Jacobs and Tavitian,
2012). Increased cerebrovascular permeability has been demon-
strated in mice challenged with the collagen-induced arthritis
(CIA) model (Nishioku et al., 2011). The same group have also
proposed that the S100A4 protein mediates disruption of the
BBB by increasing vascular permeability (Nishioku et al., 2011).
Further evidence that the BBB is not as immunologically a priv-
ileged site as previously thought is supported by the recent
observations in mice with systemic inflammation triggered by a
peripheral LPS challenge show activation of interferon-stimulated
genes (ISGs) and TNFα in the brain (Thomson et al., 2014), as
illustrated in Figure 1. Chronic inflammatory diseases, including
RA, are observationally associated with neuropsychiatric features
such as depression, anxiety, pain and fatigue. It was thought that
these features were simply secondary to the peripheral manifesta-
tions of the disease. However, the above findings suggest the BBB
may be more porous in RA (Nishioku et al., 2011)and that intrac-
erebral TNFα activity has been demonstrated and (Thomson
et al., 2014), thus, opens the possibility of a primary, cerebral
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FIGURE 1 | Scheme depicting the mechanism of neuro-inflammation in
autoimmune conditions. In this depiction lipopolysaccharide (LPS) is the
inflammatory agent which causes activation of monocytes in the systemic
circulation via Toll-Like Receptor 4 (TLR4). LPS/TLR4 activation results in the
production of pro-inflammatory cytokines (including Tumor Necrosis Factor
alpha (TNFα) and Interferon Stimulating Genes (ISGs) which activate
microglial cells within the brain. Activated monocytes are then recruited
across the BBB and as a result of all of the above there may be consequential
neuronal apoptosis and necrosis. In a model of collagen-induced arthritis,
S100 was shown to increase BBB permeability to inflammatory cells.
etiology for neuropsychiatric symptoms as proposed by Rech et al.
(2013).
The influence of infections in triggering and then maintain-
ing a pro-inflammatory response in RA is not fully understood.
Laboratory-based studies have focused on the well-characterized
pro-inflammatory response induced by agents such as LPS, which
is clearly specific to gram negative bacteria. However, the risk
of infection for patients on biologics for RA can also be influ-
enced by patient characteristics including age, disease activity,
leukopoenia, with co-morbidities including dementia, chronic
lung disease, alcoholism and diabetes mellitus, baseline steroid
use and female sex. An early systematic review of risk of seri-
ous infections in 5014 patients with RA taking anti-TNF ther-
apy (infliximab and adalimumab with etanercept excluded due
to differences in structure) in placebo-controlled trials found
that serious infections requiring anti-microbial therapy or hos-
pitalization occurred in 126 patients in the treatment arm and
26 patients on placebo (Bongartz et al., 2006). This demon-
strated an increased risk of infection with an odds ratio of 2.0,
which changed to 2.3 when stratified for dose (Bongartz et al.,
2006). Similar findings have been found in other studies with a
2.7–2.8-fold increase in serious infections associated with inflix-
imab and etanercept treatment (Listing et al., 2005) and an
incidence rate of 1.79 with subcutaneous abatacept (Alten et al.,
2014).
The most recent systematic review at the time of writing was
an analysis of data to inform an update of EULAR recommen-
dations for biologic therapies. This review concluded that most
articles referring to serious infection demonstrated a significantly
increased risk of infection in those treated with anti-TNF therapy
when compared to conventional DMARD treatment (adjusted
hazard ratio 1.0–1.7) (Ramiro et al., 2014).
A meta-analysis and simple pooling of data from 18 studies
(8808 subjects) was used by Leombruno and colleagues to investi-
gate the safety of TNF inhibitor therapy in RA (Leombruno et al.,
2009). Etanercept was included in the analysis as the investigators
considered that similarities out-weighed the differences between
the agents. In this study there was no significant difference in the
rate of serious infections between patients on anti-TNF treatment
and those not. The mean duration of therapy was less than 1 year,
therefore the authors recommended caution in drawing conclu-
sions with regard to long-term safety of biologics. However, a
later systematic review investigating the safety of further biologic
treatment after initial anti-TNF failure found that serious infec-
tion rates were not significantly different to placebo (although
only four trials met the eligibility criteria for the review) (Schoels
et al., 2012), lending weight to the findings of Leombruno et al.
(2009). A further meta-analysis of 12 randomized controlled tri-
als investigating the risk of serious infections during rituximab,
abatacept, and anakinra treatment for RA found no increased risk
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of infections for abatacept, rituximab or low-dose anakinra but
an increased risk for high-dose anakinra (OR 3.4) (Salliot et al.,
2009).
The risk of infection for patients on biologic therapy is
affected by the other medications used to treat the condition. A
study by Germano and colleagues demonstrated that, compared
to the incidence ratio of infection in patients taking conven-
tional DMARDS and corticosteroids, those taking anti-TNF and
DMARDS had a two-fold increase in incidence ratio, and those
taking anti-TNF and corticosteroids had a three-fold increase
in incidence ratio (Germano et al., 2014). This dropped to a
2.5-fold increase with anti-TNF, corticosteroid and DMARD sug-
gesting that corticosteroids increase the risk of infection when
used with anti-TNF. Infection risk (though not serious infection
risk) whilst taking adalimumab has been shown to increase with
increasing dose of concurrent methotrexate therapy in biologic
and DMARD naïve patients (Burmester et al., 2014). The risk of
infections appears to vary depending on the biologic agent, with
studies showing that opportunistic infections were less common
when using etanercept compared to the monoclonal agents inflix-
imab (OR 17.6) and adalimumab (OR 10.0) (Salmon-Ceron et al.,
2011).
TIMING OF INFECTIONS IN THE CONTEXT OF ANTI-TNF OR
IMMUNOSUPPRESSANT TREATMENT
Animal models have shown the peak of reported effects in the
brain to occur within a few hours following the acute phase
response (Serrats and Sawchenko, 2009). Peripheral LPS injection
in mice has been shown to elicit Interferon Stimulating Genes
(ISG) induction between 6 and 48 h after exposure (Thomson
et al., 2014). However, Thomson and colleagues found that the
ISG up regulation was not wholly TNF dependent, as shown by
the lack of up regulation of all ISGs with TNFα alone (Thomson
et al., 2014). The same group showed that IL-1beta and TNF alpha
were both independently up regulated in the brain followingmul-
tiple LPS challenges (Thomson et al., 2014). Nadeau and Rivest
(1999) have also suggested that LPS can have rapid effects on the
hypothalamic-pituitary-adrenal axis was determined by measur-
ing the transcriptional activity of corticotropin-releasing factor
and plasma corticosterone levels. It is therefore conceivable that
clinical RA disease activity, which can flare after acute infection,
may also be linked to neuro-inflammation during episodes of
clinical infection.
Askling andDixon (2008) found that infection risk was highest
in the first few months of anti-TNF treatment, and then declined
in frequency. This effect was echoed in another study demon-
strating that the risk of serious infection was greater at 12 weeks
duration of TNF inhibitor therapy (odds ratio 2.08) than at 104
weeks duration (odds ratio 0.97). This finding may be due to
a shift in the drug safety profile of TNF inhibitor agents, with
persistent blockade of the TNF pathway leading to up-regulation
of an alternative immune pathway and thus a compensation of
immunity (Rosenblum and Amital, 2011). However, the decline
in infection risk with time may be due to confounding factors.
As the active RA is controlled by the anti-TNF agent, the dose of
immunosuppressant CS is reduced, leading to a possible recov-
ery of host immunity. It is also hypothesized that some patients
may be at an inherently higher risk of contracting infections. If
they are included within the biologic treatment arm of a ran-
domized controlled trial they may develop an infection soon after
starting therapy, the drug will then be stopped and they will
leave the cohort leaving a healthier cohort of patients. The lat-
ter is known as the “healthy user effect” (Rosenblum and Amital,
2011).
In terms of opportunistic infections (excluding TB), the
median time from commencement of treatment to time of first
opportunistic infection is 16.2 months (6.0–26.0) (Salmon-Ceron
et al., 2011), much longer than the 3 months of highest risk, sug-
gesting that immunosuppression secondary to biologics is, in fact,
delayed in onset. It should be noted that studies since that per-
formed by Dixon and colleagues (Askling and Dixon, 2008) have
shown that the risk of first serious infection was stable throughout
treatment.
Numerous murine and human models have demonstrated
how LPS-induced gram-negative infections induce inflammation
accompanied by somatic or visceral pain (Teeling et al., 2012;
Chiu et al., 2013; Thomson et al., 2014). Such features have
been attributed to sensitisation of nociceptors by inflammatory
mediators released by immune cells. Sensitisation of nociceptors
by inflammatory mediators released by peripheral immune cells
occurs through activation of the TLR4 signaling pathway by LPS
a toxic product of bacterial lysis. Meseguer et al. (2014) recently
proposed that LPS induces activation of TRPA1 in a murine
model, a transient receptor potential cation channel that tras-
duces environmental stimuli to nociceptor activity. The group
also found that acute vascular reactions, including neurogenic
inflammation as indicated by CGRP release (measured by enzyme
immunoassay), were mediated through TRPA1 and were inde-
pendent of TLR4 activation. Such observations suggest that not
only are infectious agents such as LPS inducing the pain response,
but also produce a neurovascular response which could explain
the missing link between peripheral infection and central brain
neuro-inflammation.
NEURO-IMMUNE INTERACTION IN RHEUMATOID
ARTHRITIS
Neuroinflammation is conducted, in the CNS, by microglial
cells and astrocytes through the production of pro-inflammatory
mediators and cytokines. This inflammation results in cell death
and neuronal loss. RA is characterized by chronic inflammation
which leads to a constant stimulation of nociceptor and excitation
of afferent neurons to the brain. As such it has neurological simi-
larities to a chronic pain state and central sensitization is thought
to occur in as a result (Woolf, 1983). Evidence for enhanced
hyperalgesia has been demonstrated in RA patients when com-
pared to controls using a capsaicin and pin-prick method (Morris
et al., 1997).
Lee and colleagues have suggested central sensitization as a
mechanism for explaining chronic pain in rheumatic diseases
such as RA (Lee et al., 2011). Central sensitization and changes
in nociceptive processing in response to repeated stimula-
tion by chemo-somatosensory event-related potentials (CSSERP)
have been demonstrated encephalographically in RA patients
(Wendler et al., 2001). Although increases in alpha1 and beta1
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range are thought to be secondary to a chronic pain state it may be
that these changes are in fact a result of direct neuroinflammation
secondary to the arthritis itself. Schweinhardt et al. found that
people with painful RA demonstrate higher activation of brain
regions associated with emotional cognition of pain including the
medial pre-frontal cortex (Schweinhardt et al., 2008).
Further evidence of neuro-immune interplay has also emerged
suggesting that use of biologic therapies such as TNF inhibitors
can have central brain effects in people with RA well before a
reduction of inflammation within affected joints occurs. In a
recent study functional MRI (fMRI) was used to assess the neuro-
logical effects of TNF inhibitor therapy in 10 patients with active
RA (Rech et al., 2013). The fMRI signal is sensitive to concen-
tration of deoxyhemoglobin (which is paramagnetic), hence can
detect areas of higher neuronal activity where there is greater
blood flow due to increased brain metabolism associated with a
task or stimulus (Ogawa et al., 1990). Rech et al. (2013) analyzed
the fMRI response to compression of finger joints in RA patients
at baseline and 3, 7, and 28 days after subcutaneous treatment
with the TNF inhibitor adalimumab. Clinical disease activity was
assessed at the same time points by applying the validated DAS28
(Disease Activity Score), which is based on the assessment of the
number of swollen and tender joints, the ESR and the patient’s
global rating of disease activity. Inflammatory tissue was also
measured anatomically by MRI of the dominantly affected hand
at baseline and 28 days. At baseline there was a greater volume of
functional activation in response to finger joint compression of
the patients that responded to TNF treatment than those that did
not respond. The main regions activated by joint compression at
baseline were the somatosensory cortex, insular cortex and dor-
solateral prefrontal cortex, thus suggesting a greater perception of
pain. However, the brain activation was then significantly reduced
as early as 3 days after treatment and further decreased after
7 days, whereas the disease activity score was only significantly
reduced by day 28. Data from this study support the concept that
chronic inflammation in RA leads to central sensitization, with
the possibility of modulating pain perception with appropriate
treatment.
A neuro-immune interaction is not isolated to RA or TNFα.
Neuropsychiatric symptoms have shown improvement with
cytokine blockade, for example IL-1 inhibition in Sjögrens and
diabetes mellitus reduced fatigue (Norheim et al., 2012) Within
“pure” neuroinflammatory disorders such as Alzheimer’s there
is increasing murine data to show an improvement in memory
and reduced hippocampal TNFα levels as a result of anti-TNFα
receptor fusion protein administration (Detrait et al., 2014). This
has lead to a move toward considering anti-TNFα as a ther-
apy for Alzheimer’s dementia (Cheng et al., 2014) Auanofin,
a gold—containing medication and established treatment for
RA, dampens inflammation through manipulation of the anti-
and pro-inflammatory interleukin balance. Interestingly a recent
in vitro study has demonstrated a reduced production of cytotoxic
mediators by microglia in response to gold therapy (Medeiros
et al., 2007).
Diamond and Tracey recently proposed the concept of the
immunological homunculus of the brain (Diamond and Tracey,
2011) where the brain acts as a sensory organ, allowing real-time
transmission of information such as infections, tissue damage
and inflammation to the central nervous system. Indeed, they
draw attention to the concept of an “inflammatory reflex,” in
which the neurotransmitter acetyl choline interacts with cytokine
production via α7 nicotinic acetylcholine receptors on immune
cells.
MAGNETIC RESONANCE IMAGING IN RHEUMATOID
ARTHRITIS
Magnetic resonance imaging (MRI) provides a variety of tech-
niques for assessing neurological involvement of disease processes
by detecting changes in brain morphometry [T1 weighted imag-
ing (T1w)] and tissue microstructure [T2 weighted imaging
(T2w), diffusion weighted imaging (DWI), diffusion tensor imag-
ing (DTI), and magnetisation transfer imaging (MTI)], brain
metabolism by magnetic resonance spectroscopy (MRS) and
actual brain functionality by fMRI as described above. However,
there are far fewer reports of neuroimaging abnormalities for
RA compared to other related autoimmune diseases. In Sjögren’s
syndrome significant loss of brain tissue and presence of white
matter lesions are observed (Akasbi et al., 2012; Lauvsnes et al.,
2014).Lupus can lead to microstructural changes in white matter
(WM), white matter lesions and metabolic abnormalities (Axford
et al., 2001; Zivadinov et al., 2013) with associated neuropsycho-
logical sequelae. A summary of the imaging techniques utilized
so far in demonstrating inflammatory changes in autoimmune-
mediated conditions is summarized in Table 1.
T2 weighted imaging allows detection of lesions associated
with inflammatory and degenerative changes in the brain and
in terms of number and size of WM hyperintensities, lesion
load is higher with age in the normal population and associ-
ated with microvascular disease (King et al., 2014). A quantitative
T2w MRI study showed no significant difference in WM lesion
load between RA patients and controls (Bekkelund et al., 1995)
although WM lesions in RA patients have been associated with
higher levels of the protein S100B, a potential plasma marker
of BBB disruption and neurodegenerative effects (Hamed et al.,
2012). Hamed and colleagues performed cognitive testing and
found that RA patients had greater depression than controls,
but this did not correlate with cognitive scores, whereas cogni-
tion did correlate with S100B levels (Hamed et al., 2012). In a
rodent model of arthritis the presence of the inflammation stimu-
lated protein S100A4 was strongly associated with BBB disruption
(Nishioku et al., 2011). Thus a cerebrovascular component is
likely in RA, but not one specifically detectable by conventional
MRI in the general RA population.
T1 weighted imaging provides high spatial resolution of the
brain with excellent contrast between gray and white matter
structures to allow assessment of the shape and size of different
anatomical regions. A recent study with T1w MRI demonstrated
no global difference of intracranial volume between RA patients
and controls, but observed significant increases in the volume of
basal ganglia structures (Wartolowska et al., 2012). The caudate
nucleus in particular showed the most significant increase, sug-
gesting these changes are related to pain processing rather than
the disease itself. However, there are reports of both increased and
decreased gray matter structure volumes in patients with chronic
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Table 1 | A table displaying the imaging modalities used to investigate neuroinflammation.
Imaging modality Method of action Relevance to rheumatoid arthritis
T2-Weighted MRI Inflammatory and degenerative changes are
demonstrated in the form of white matter
hyperintensities
White matter lesions are associated with higher levels of S100B
which is a potential surrogate marker for blood brain barrier
disruption (Hamed et al., 2012)
T1-Weighted MRI Provides high spatial resolution imaging of the brain
allowing volumetric assessment of cerebral anatomy
Has demonstrated increased volume of basal ganglia in RA
patients compared to controls (Steens et al., 2005)
Diffusion weighted
imaging
Quantitative parameters relate to neuronal density,
structural integrity and water content
Potential for assessing inflammatory and neurodegenerative
changes (Steens et al., 2005; Zivadinov et al., 2013)
Magnetisation
transfer imaging
Quantitative parameters relate to magnetisation
exchange between macromolecules (e.g., myelin,
proteins) and bulk tissue water
Potential for assessing inflammatory and neurodegenerative
changes (Steens et al., 2005)
Magnetic resonance
spectroscopy
Relative levels of specific metabolites, including N-acetyl
aspartate, creatine, choline, myo-Inositol and some
neurotransmitters
Increased choline/creatine ratio is proportional to rise in ESR and
disease activity
Increased choline levels seen in neuroinflammation in systemic
lupus (Axford et al., 2001; Emmer et al., 2009)
pain indicating there may be a complex mix of neurodegener-
ative or adaptive changes dependent on disease, duration and
consequent lifestyle changes, as well as treatment (Wartolowska
et al., 2012). Currently it is known that only in patients with
longstanding (i.e., >15 years) RA is there a reduction in brain
volume that may relate to neurodegenerative changes caused by
RA (Bekkelund et al., 1995).
Treatment for RA commonly includes CS to reduce inflam-
mation and the effect of low-dose CS treatment on the brain
has been investigated with quantitative MRI (Steens et al., 2005).
Parameters derived from DWI and MTI relate to neuronal den-
sity and myelin-tissue water magnetisation exchange respec-
tively, hence are sensitive to inflammatory and neurodegenerative
changes. Whole brain histograms of the apparent diffusion coeffi-
cient (ADC) and magnetization transfer ratio (MTR) showed no
significant difference between controls and RA patients with or
without CS treatment. Although the results of Steens et al. (2005)
indicate no global differences of MRI parameters, a more focused
study that separates gray and white matter structures is war-
ranted as performed for lupus and with the increased sensitivity
of modern 3T MRI systems (Zivadinov et al., 2013). In addition,
DTI has much greater sensitivity than DWI to detect microstruc-
tural changes in WM, and can provide detailed anatomical maps
that describe regional differences of neurodegenerative change
(Barrick et al., 2010).
There is some evidence of metabolic changes in the brain due
to RA. In the Steens study (Steens et al., 2005) 1HMRS of a single
white matter region adjacent to the left ventricle almost reached
a significant difference in metabolite levels between RA patients
and controls. A subsequent retrospective analysis showed that a
high choline to creatine (Cho/Cr) metabolite ratio was associ-
ated with high ESR levels and correlated with ESR and disease
activity after correction for disease activity and duration (Emmer
et al., 2009). There was no difference in N-acetyl aspartate to crea-
tine (NAA/Cr) ratio or correlation with ESR, suggesting there was
no neuronal damage, which is consistent with the lack of major
neurological symptoms in RA, unlike for lupus. Elevated choline
is found in lupus and other neuroinflammatory diseases (Axford
et al., 2001). Choline has a function in cell membrane synthe-
sis and its elevation in RA may relate to microglial activation
or monocyte infiltration (Emmer et al., 2009). Brain metabolic
changes have been associated with pain processing regions in
a number of studies and elevation of the combined neuro-
transmitters glutamate and glutamine observed in fibromyalgia
patients (Fayed et al., 2010) and also with induced pain (Gussew
et al., 2010). The significance of these results for development of
novel treatment or monitoring treatment response is yet to be
established.
To date there are far fewer neuroimaging studies in RA patients
compared to other diseases with cerebrovascular, neuroinflam-
matory and neurodegenerative components (e.g., stroke, lupus
and dementias). This reflects the lower incidence of neurolog-
ical symptoms and the more subtle effects of cerebrovascular
involvement that have been so far detected.
CONCLUSION
The concept of neuroinflammation as a significant component of
disease pathophysiology in RA has only recently been recognized.
Animal models have recently demonstrated that infectious agents
including LPS can directly activate the immune system stimulate
pain responses. Coupled with the strong link between RA and
incidence of infection, it may be time to reconsider the balance
between maintaining disease remission using disease-modifying
immune-modulatory drugs and preventing disease flares induced
by infection. However, the link between infection and immune-
modulatory therapies remains controversial and comparison of
studies is made difficult by differing biologic therapies used,
different diseases treated and different, concurrent medications
regimes. Further, high-powered studies are required to establish
the period of highest risk and susceptibility to infections and the
overall risk of infections for patients taking biological treatments
for RA.
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Future work is needed to understand how the RA disease pro-
cess impacts on pain activation in RA, whether sensitisation is
a general phenomenon in RA or found in specific subsets of
patients and what specific infectious triggers contribute to an
autoimmune pro-inflammatory network that leads to chronic
pain and inflammation.
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